公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply | Finn R.S.; ANN-LII CHENG | The New England journal of medicine | 2 | 8 | |
2020 | Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma | Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG ; IMbrave150 Investigators | New England Journal of Medicine | 3470 | 3126 | |
2021 | Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study | Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG | Liver Cancer | 62 | 49 | |
2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 38 | 39 | |
2013 | The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme | Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F. | Oncology | 11 | 9 | |
2018 | Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells | Wu C.-H.; Yang Y.-H.; MEI-RU CHEN ; CHING-HWA TSAI ; ANN-LII CHENG ; SHIN-LIAN DOONG | PLoS ONE | 3 | 2 | |
2015 | AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-B activation | Tsai H.-J.; Shih N.-Y.; SUNG-HSIN KUO ; ANN-LII CHENG ; Lin H.-Y.; Chen T.-Y.; Chang K.-C.; Lin S.-F.; Chang J.S.; Chen L.-T. | Leukemia and Lymphoma | 7 | 1 | |
2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
2017 | The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21) | SUNG-HSIN KUO ; Tsai H.-J.; CHUNG-WU LIN ; KUN-HUEI YEH ; Lee H.-W.; Wei M.-F.; CHIA-TUNG SHUN ; MING-SHIANG WU ; PING-NING HSU ; Chen L.-T.; ANN-LII CHENG | Journal of Pathology | 12 | 12 | |
2002 | Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells | Chuang S.-E.; Yeh P.-Y.; YEN-SHEN LU ; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG | Biochemical Pharmacology | 161 | 138 | |
1998 | Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity | Kuo M.-L.; Shen S.-C.; CHIH-HSIN YANG ; Chuang S.-E.; ANN-LII CHENG ; Huang T.-S. | Oncogene | 39 | 35 | |
2012 | BCL10GFP fusion protein as a substrate for analysis of determinants required for mucosa-associated lymphoid tissue 1 (MALT1)-mediated cleavage | Jou, Shin-Yi; Chang, Chien-Chih; Wu, Chun-Hsien; MEI-RU CHEN ; CHING-HWA TSAI ; Chuang, Wen-Hui; Chen, Yun-Hui; ANN-LII CHENG ; SHIN-LIAN DOONG | Journal of biomedical science | 1 | | |
2016 | Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis | I-CHUN CHEN ; CHING-HUNG LIN ; I-SHIOW JAN ; ANN-LII CHENG ; YEN-SHEN LU | Journal of the Formosan Medical Association | 18 | 11 | |
2015 | Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy | YEN-SHEN LU ; WEI-WU CHEN ; CHING-HUNG LIN ; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; BANG-BIN CHEN ; Chao T.-C.; Huang S.-M.; CHIUN-SHENG HUANG ; TIFFANY TING-FANG SHIH ; ANN-LII CHENG ; Taiwan Breast Cancer Consortium | Clinical Cancer Research | 65 | 59 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2014 | Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse | SUNG-HSIN KUO ; Tsai H.-J.; Weng W.-H.; Li C.-C.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 3 | 3 | |
1998 | Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma | ANN-LII CHENG ; KUN-HUEI YEH ; Fine R.L.; Chuang S.-E.; Yang C.-H.; Wang L.-H.; DING-SHINN CHEN | Hepato-Gastroenterology | 41 | 33 | |
1989 | Bone marrow involvement in non-Hodgkin's lymphoma. | HONG-SHIEE LAI ; HWEI-FANG TIEN ; Hsieh H.C.; YAO-CHANG CHEN ; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG ; MING-CHING SHEN ; Liu C.H. | Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association | 11 | 0 | |
2012 | Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A | CHAO YUAN HUANG ; CHIA-CHENG WEI ; Chen K.-C.; Chen H.-J.; ANN-LII CHENG ; Chen K.-F. | Cancer Letters | 29 | 28 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |